| Name | Title | Contact Details |
|---|---|---|
John Phillips |
Vice President of Sales | Profile |
James Drob |
Head of Aseptic Manufacturing, Supply Chain and Validation | Profile |
Joseph Kiely |
Chief Financial Officer | Profile |
Alexander Borodin |
Senior Director of Supply Chain | Profile |
George Sanders |
Vice President of Human Resources | Profile |
Groupe Essaim Inc. is a Boucherville, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Restoring hope and providing healing services for children and families in Central and Southwestern Ohio - from mental health treatment to foster care.
Valcour Strategic Group is a Peru, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
EZ-MED is a Pompano Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Harpoon Therapeutics is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that harness the power of the body`s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient`s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. Harpoon`s third proprietary technology platform, extended release TriTAC-XR, is designed to mitigate cytokine release syndrome.